Topic Highlight
Copyright ©2014 Baishideng Publishing Group Co.
World J Gastroenterol. Apr 28, 2014; 20(16): 4526-4535
Published online Apr 28, 2014. doi: 10.3748/wjg.v20.i16.4526
Table 3 Overview of the phase II and III compounds and their targets
CompoundsType of compoundTarget(s)Clinical phase
Dacomitinib (PF-00299804, Pfizer)Irreversible pan-HER TKIHER1 (EGFR) and HER2II
Afatinib (Gilotrif, Boehringer Ingelheim)Irreversible pan-HER TKIHER1 (EGFR), HER2, and HER4II
Pertuzumab (Perjeta, Roche/Genentech)mAbHER2 (subdomain II), HER2 hetero dimerizationII/III
Ado-trastuzumab emtansine (Kadcyla, Roche/Genentech)ADCHER2 (subdomain IV)II/III
Lapatinib (Tyverb/Tykerb, GSK)Reversible pan-HER TKIHER1 (EGFR) and HER2III

Citation: Jørgensen JT. Role of human epidermal growth factor receptor 2 in gastric cancer: Biological and pharmacological aspects. World J Gastroenterol 2014; 20(16): 4526-4535